TY - JOUR
T1 - Real-world management of treatment-naïve diabetic macular oedema
T2 - 2-year visual outcome focusing on the starting year of intervention from STREAT-DMO study
AU - Shimura, Masahiko
AU - Kitano, Shigehiko
AU - Muramatsu, Daisuke
AU - Fukushima, Harumi
AU - Takamura, Yoshihiro
AU - Matsumoto, Makiko
AU - Kokado, Masahide
AU - Kogo, Jiro
AU - Sasaki, Mariko
AU - Morizane, Yuki
AU - Utsumi, Takuya
AU - Koto, Takashi
AU - Sonoda, Shozo
AU - Hirano, Takao
AU - Ishikawa, Hiroto
AU - Mitamura, Yoshinori
AU - Okamoto, Fumiki
AU - Kinoshita, Takamasa
AU - Kimura, Kazuhiro
AU - Sugimoto, Masahiko
AU - Yamashiro, Kenji
AU - Suzuki, Yukihiko
AU - Hikichi, Taiichi
AU - Washio, Noriaki
AU - Sato, Tomohito
AU - Ohkoshi, Kishiko
AU - Tsujinaka, Hiroki
AU - Kusuhara, Sentaro
AU - Kondo, Mineo
AU - Takagi, Hitoshi
AU - Murata, Toshinori
AU - Sakamoto, Taiji
N1 - Funding Information:
Funding This study was supported by clinical research grant-in aid by Tokyo Medical University. This study is registered with the University Hospital Medical Information Network individual case data repository (UMIN#23160).
PY - 2020/12/1
Y1 - 2020/12/1
N2 - Background/aims To investigate the yearly change of real-world outcomes for best corrected visual acuity (BCVA) after 2-year clinical intervention for treatment-naïve diabetic macular oedema (DMO). Methods Retrospective analysis of aggregated, longitudinal medical records obtained from 27 retina specialised institutions in Japan from Survey of Treatment for DMO database. A total of 2049 treatment-naïve centre involving DMO eyes of which the initial intervention started between 2010 and 2015, and had been followed for 2 years, were eligible. As interventions, antivascular endothelial growth factor (VEGF) agents, local corticosteroids, macular photocoagulation and vitrectomy were defined. In each eye, baseline and final BCVA, the number of each intervention for 2 years was extracted. Each eye was classified by starting year of interventional treatment. Results Although baseline BCVA did not change by year, 2-year improvement of BCVA had been increased, and reached to +6.5 letters in the latest term. There is little difference among starting year about proportions of eyes which BCVA gained >15 letters, in contrast to those which lost >15 letters were decreased by year. The proportion of eyes receiving anti-VEGF therapy was dramatically increased, while those receiving the other therapies were gradually decreased. The proportion of eyes which maintained socially good vision of BCVA>20/40 has been increased and reached to 59.0% in the latest term. Conclusion For recent years, treatment patterns for DMO have been gradually but certainly changed; as a result, better visual gain, suppression of worsened eyes and better final BCVA have been obtained. Anti-VEGF therapy has become the first-line therapy and its injection frequency has been increasing.
AB - Background/aims To investigate the yearly change of real-world outcomes for best corrected visual acuity (BCVA) after 2-year clinical intervention for treatment-naïve diabetic macular oedema (DMO). Methods Retrospective analysis of aggregated, longitudinal medical records obtained from 27 retina specialised institutions in Japan from Survey of Treatment for DMO database. A total of 2049 treatment-naïve centre involving DMO eyes of which the initial intervention started between 2010 and 2015, and had been followed for 2 years, were eligible. As interventions, antivascular endothelial growth factor (VEGF) agents, local corticosteroids, macular photocoagulation and vitrectomy were defined. In each eye, baseline and final BCVA, the number of each intervention for 2 years was extracted. Each eye was classified by starting year of interventional treatment. Results Although baseline BCVA did not change by year, 2-year improvement of BCVA had been increased, and reached to +6.5 letters in the latest term. There is little difference among starting year about proportions of eyes which BCVA gained >15 letters, in contrast to those which lost >15 letters were decreased by year. The proportion of eyes receiving anti-VEGF therapy was dramatically increased, while those receiving the other therapies were gradually decreased. The proportion of eyes which maintained socially good vision of BCVA>20/40 has been increased and reached to 59.0% in the latest term. Conclusion For recent years, treatment patterns for DMO have been gradually but certainly changed; as a result, better visual gain, suppression of worsened eyes and better final BCVA have been obtained. Anti-VEGF therapy has become the first-line therapy and its injection frequency has been increasing.
KW - epidemiology
KW - macula
KW - retina
UR - http://www.scopus.com/inward/record.url?scp=85082202896&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85082202896&partnerID=8YFLogxK
U2 - 10.1136/bjophthalmol-2019-315726
DO - 10.1136/bjophthalmol-2019-315726
M3 - Article
C2 - 32169861
AN - SCOPUS:85082202896
VL - 104
SP - 1755
EP - 1761
JO - British Journal of Ophthalmology
JF - British Journal of Ophthalmology
SN - 0007-1161
IS - 12
ER -